Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:EDIT
- CUSIP: N/A
- Web: www.editasmedicine.com
Capitalization:- Market Cap: $953.67 million
- Outstanding Shares: 35,840,000
Average Prices:- 50 Day Moving Avg: $20.92
- 200 Day Moving Avg: $20.92
- 52 Week Range: $12.43 - $28.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.31
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $5.64 million
- Price / Sales: 134.21
- Book Value: $3.76 per share
- Price / Book: 5.62
Profitability:- EBIDTA: ($114,840,000.00)
- Net Margins: -2,091.36%
- Return on Equity: -67.75%
- Return on Assets: -38.19%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 6.74%
- Quick Ratio: 6.74%
Misc:- Average Volume: 1.29 million shs.
- Beta: 4.78
- Short Ratio: 13.74
Frequently Asked Questions for Editas Medicine (NASDAQ:EDIT)
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. The business earned $3.10 million during the quarter, compared to analysts' expectations of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The company's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) earnings per share. View Editas Medicine's Earnings History.
When will Editas Medicine make its next earnings announcement?
Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?
8 brokers have issued 1 year price targets for Editas Medicine's shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $26.75 in the next year. View Analyst Ratings for Editas Medicine.
What are analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. Cann analysts commented, "Editas’ loss per share was $0.65, compared to our estimated loss of $1.01. This was the result of higher than expected collaborative revenue, lower than estimated operating expenses and higher than estimated shares outstanding." (8/10/2017)
- 2. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (7/18/2017)
- 3. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
- 4. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
- 5. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Immunomedics (IMMU), Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Momenta Pharmaceuticals (MNTA), Esperion Therapeutics (ESPR), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA) and Spectrum Pharmaceuticals (SPPI).
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Katrine S. Bosley, President, Chief Executive Officer, Director
- Andrew A. F. Hack, Chief Financial Officer
- Charles Albright, Chief Scientific Officer
- Gerald Cox, Chief Medical Officer
- Andrew Hirsch, Director
- Akshay K. Vaishnaw M.D., Ph.D., Director
- Kevin J. Bitterman Ph.D., Independent Director
- Alexis Borisy, Independent Director
- Douglas G. Cole M.D., Independent Director
When did Editas Medicine IPO?
(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who owns Editas Medicine stock?
Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.70%), Flagship Pioneering Inc. (8.29%), Vanguard Group Inc. (5.35%), Capital World Investors (4.32%), State Street Corp (1.31%) and ARK Investment Management LLC (1.25%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, James E Flynn, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.
Who sold Editas Medicine stock? Who is selling Editas Medicine stock?
Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, TD Asset Management Inc., Cim Investment Mangement Inc. and Victory Capital Management Inc.. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Katrine Bosley, Kevin Bitterman and Polaris Venture Management Co. View Insider Buying and Selling for Editas Medicine.
Who bought Editas Medicine stock? Who is buying Editas Medicine stock?
Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, ARK Investment Management LLC, Northern Trust Corp, Vanguard Group Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Nisa Investment Advisors LLC and Greenwoods Asset Management Ltd. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and James E Flynn. View Insider Buying and Selling for Editas Medicine.
How do I buy Editas Medicine stock?
Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of Editas Medicine stock can currently be purchased for approximately $21.12.
MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $26.75 (26.66% upside) |
Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/6/2017 | Barclays PLC | Initiated Coverage | Overweight | $19.69 -> $28.00 | Medium |  |
| 8/9/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $27.00 | High | |
| 8/10/2017 | Cann | Reiterated Rating | Hold | | High | |
| 7/18/2017 | Oppenheimer Holdings, Inc. | | Market Perform | | N/A | |
| 7/13/2017 | SunTrust Banks, Inc. | Initiated Coverage | Hold -> Hold | $17.00 | High | |
| 3/27/2017 | Chardan Capital | Initiated Coverage | Buy -> Buy | | High | |
| 3/15/2017 | Cowen and Company | Reiterated Rating | Buy | | Low | |
| 2/15/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $35.00 | N/A | |
| 2/29/2016 | Morgan Stanley | Initiated Coverage | Equal -> Equal Weight | $28.00 | N/A | |
| 2/29/2016 | JMP Securities | Initiated Coverage | Outperform | $40.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Editas Medicine (NASDAQ:EDIT)Earnings History by Quarter for Editas Medicine (NASDAQ EDIT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.60) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($0.64) | ($0.65) | $2.20 million | $3.10 million | View | Listen | |
| 5/15/2017 | Q1 2017 | ($0.62) | ($0.85) | $1.00 million | $0.68 million | View | N/A | |
| 3/7/2017 | Q4 2016 | ($0.62) | ($1.10) | $1.11 million | $0.90 million | View | Listen | |
| 11/7/2016 | Q3 | ($0.64) | ($0.59) | $1.00 million | $1.00 million | View | Listen | |
| 8/9/2016 | Q2 | ($0.54) | ($0.54) | $3.52 million | $3.39 million | View | Listen | |
| 5/16/2016 | Q116 | ($0.23) | ($0.80) | $1.08 million | $0.80 million | View | Listen | |
| 3/30/2016 | Q4 | ($0.52) | ($4.05) | | $0.79 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Editas Medicine (NASDAQ:EDIT)2017 EPS Consensus Estimate: ($3.07)
2018 EPS Consensus Estimate: ($4.38)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.66) | ($0.66) | ($0.66) |
| Q2 2017 | 1 | ($0.70) | ($0.70) | ($0.70) |
| Q3 2017 | 3 | ($0.75) | ($0.67) | ($0.72) |
| Q4 2017 | 3 | ($1.40) | ($0.77) | ($0.99) |
| Q1 2018 | 1 | ($0.98) | ($0.98) | ($0.98) |
| Q2 2018 | 1 | ($0.85) | ($0.85) | ($0.85) |
| Q3 2018 | 1 | ($0.89) | ($0.89) | ($0.89) |
| Q4 2018 | 1 | ($1.66) | ($1.66) | ($1.66) |
(Data provided by Zacks Investment Research)
Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Editas Medicine (NASDAQ:EDIT)Insider Ownership Percentage: 19.40%
Institutional Ownership Percentage: 69.98%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/5/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.33 | $338,819.78 | |
| 9/1/2017 | Katrine Bosley | CEO | Sell | 10,000 | $20.42 | $204,200.00 | |
| 8/11/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.02 | $333,653.32 | |
| 6/2/2017 | Boris Nikolic | Director | Buy | 35,000 | $14.07 | $492,450.00 | |
| 6/2/2017 | Gerald Frank Cox | Insider | Buy | 4,000 | $14.15 | $56,600.00 | |
| 5/22/2017 | Kevin Bitterman | Director | Sell | 1,000,000 | $17.00 | $17,000,000.00 | |
| 3/15/2017 | Alexandra Glucksmann | COO | Sell | 1,000 | $26.41 | $26,410.00 | |
| 2/15/2017 | Alexandra Glucksmann | COO | Sell | 6,000 | $20.58 | $123,480.00 | |
| 2/15/2017 | Andrew A F Hack | CFO | Sell | 3,000 | $19.20 | $57,600.00 | |
| 1/11/2017 | Andrew A F Hack | CFO | Sell | 15,000 | $19.20 | $288,000.00 | |
| 12/7/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 75,000 | $15.82 | $1,186,500.00 | |
| 12/6/2016 | Kevin Bitterman | Director | Sell | 130,000 | $15.79 | $2,052,700.00 | |
| 11/23/2016 | Kevin Bitterman | Director | Sell | 21,480 | $15.71 | $337,450.80 | |
| 11/22/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 12,819 | $15.77 | $202,155.63 | |
| 11/15/2016 | Kevin Bitterman | Director | Sell | 88,900 | $16.96 | $1,507,744.00 | |
| 9/8/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 500,000 | $16.80 | $8,400,000.00 | |
| 9/6/2016 | Kevin P. Starr | Major Shareholder | Sell | 5,890 | $15.90 | $93,651.00 | |
| 8/23/2016 | Alexandra Glucksmann | COO | Sell | 1,000 | $20.00 | $20,000.00 | |
| 2/8/2016 | James E Flynn | Insider | Buy | 100,000 | $16.00 | $1,600,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Editas Medicine (NASDAQ:EDIT)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
| Source: |
|
| Date | Headline |
|---|
 | Editas Medicine, Inc. (EDIT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 25 at 2:38 AM |
 | Form 8-K Editas Medicine, Inc. For: Sep 18 - StreetInsider.com
www.streetinsider.com - September 23 at 3:18 AM |
| Brokerages Anticipate Editas Medicine, Inc. (EDIT) Will Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - September 21 at 12:20 AM |
 | Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte
www.marketwatch.com - September 15 at 6:41 PM |
 | BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10
www.reuters.com - September 12 at 11:59 PM |
 | Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type ... - GlobeNewswire (press release)
globenewswire.com - September 12 at 6:55 PM |
 | Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
finance.yahoo.com - September 12 at 6:55 PM |
| Editas Medicine Inc (EDIT) Coverage Initiated by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:52 PM |
 | Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August - Motley Fool
www.fool.com - September 9 at 4:58 AM |
 | Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
www.nasdaq.com - September 7 at 6:15 PM |
| Editas Medicine, Inc. (EDIT) CEO Sells $204,200.00 in Stock
www.americanbankingnews.com - September 6 at 8:50 PM |
| Editas Medicine, Inc. (EDIT) Insider Sells $338,819.78 in Stock
www.americanbankingnews.com - September 6 at 8:28 PM |
| Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 7:48 PM |
| Editas Medicine, Inc. (EDIT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 31 at 2:46 AM |
| This Stock Could Be the Tesla of Healthcare
finance.yahoo.com - August 28 at 3:24 AM |
| Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% - Nasdaq
www.nasdaq.com - August 16 at 6:33 PM |
| $2.55 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter
www.americanbankingnews.com - August 16 at 2:32 AM |
| Insider Selling: Editas Medicine, Inc. (EDIT) Insider Sells 16,666 Shares of Stock
www.americanbankingnews.com - August 14 at 11:10 PM |
| [$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns
finance.yahoo.com - August 14 at 6:29 PM |
| Q3 2017 EPS Estimates for Editas Medicine, Inc. Lifted by Oppenheimer Holdings (EDIT)
www.americanbankingnews.com - August 14 at 3:18 AM |
| Editas Medicine, Inc. (EDIT) to Post Q3 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 14 at 3:18 AM |
| Edited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT
finance.yahoo.com - August 10 at 7:26 PM |
| Editas Medicine, Inc. (NASDAQ:EDIT) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - August 9 at 11:58 PM |
| Editas Medicine (EDIT) to Receive $2.5M for Milestone Under Juno Therapeutics Collaboration
www.streetinsider.com - August 9 at 11:23 PM |
| Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:21 PM |
| Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
finance.yahoo.com - August 9 at 6:21 PM |
| Editas Medicine Announces Second Quarter 2017 Results and Update
finance.yahoo.com - August 9 at 6:21 PM |
| Editas reports 2Q loss
finance.yahoo.com - August 9 at 6:21 PM |
| Here's Why Editas Medicine Rose as Much as 15.9% Monday - Motley Fool
www.fool.com - August 9 at 3:58 AM |
| Here's Why Editas Medicine Rose as Much as 15.9% Monday
finance.yahoo.com - August 8 at 5:55 PM |
| Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
finance.yahoo.com - August 7 at 6:27 PM |
| Editas Medicine, Inc. (EDIT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 6 at 7:10 AM |
 | Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
www.thestreet.com - August 3 at 12:04 AM |
 | Biotech Stock Performance Review -- Celgene, Cempra, Editas Medicine, and Epizyme - PR Newswire (press release)
www.prnewswire.com - July 31 at 5:55 PM |
| Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31, 2017
finance.yahoo.com - July 31 at 5:55 PM |
| Editas Medicine, Inc. (NASDAQ:EDIT) Expected to Announce Quarterly Sales of $2.88 Million
www.americanbankingnews.com - July 29 at 7:27 AM |
| Analysts Expect Editas Medicine, Inc. (EDIT) to Post -$0.64 EPS
www.americanbankingnews.com - July 27 at 2:26 PM |
| ETFs with exposure to Editas Medicine, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:56 PM |
| Oppenheimer Holdings Comments on Editas Medicine, Inc.'s FY2017 Earnings (EDIT)
www.americanbankingnews.com - July 20 at 10:35 AM |
| Editas Medicine, Inc. (EDIT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 10:20 PM |
| Cann Initiates Coverage on Editas Medicine, Inc. (NASDAQ:EDIT)
www.americanbankingnews.com - July 17 at 7:15 PM |
| SunTrust Banks, Inc. Initiates Coverage on Editas Medicine, Inc. (EDIT)
www.americanbankingnews.com - July 16 at 5:14 PM |
 | Benzinga's Top Upgrades, Downgrades For July 14, 2017 - Benzinga
www.benzinga.com - July 14 at 3:09 PM |
| ETFs with exposure to Editas Medicine, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:09 PM |
| Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 12 at 10:11 PM |
| Editas Medicine, Inc. (NASDAQ:EDIT) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM |
| Here's Why Editas Medicine Inc. Bounced Up 20% in June -- The ... - Motley Fool
www.fool.com - July 12 at 12:18 AM |
| Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11, 2017
finance.yahoo.com - July 11 at 7:18 PM |
| Here's Why Editas Medicine Inc. Bounced Up 20% in June
finance.yahoo.com - July 11 at 7:18 PM |
| Editas Medicine, Inc. – Value Analysis (NASDAQ:EDIT) : July 3, 2017
finance.yahoo.com - July 3 at 6:01 PM |
Editas Medicine (EDIT) Chart for Tuesday, September, 26, 2017
